{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.35","upperLimit":"0.77","value":"0.52"},{"groupId":"OG001","lowerLimit":"0.29","upperLimit":"0.55","value":"0.40"},{"groupId":"OG002","lowerLimit":"0.54","upperLimit":"0.94","value":"0.71"},{"groupId":"OG003","lowerLimit":"0.75","upperLimit":"0.95","value":"0.84"},{"groupId":"OG004","lowerLimit":"0.75","upperLimit":"0.95","value":"0.85"},{"groupId":"OG005","lowerLimit":"0.74","upperLimit":"1.00","value":"0.87"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"55"},{"groupId":"OG004","value":"54"},{"groupId":"OG005","value":"24"}],"units":"Participants"}],"description":"Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. The 6-month progression free survival rate is the proportion of evaluable patients progression-free 6 months from registration. The 6-month progression-free rate is defined as the total number of efficacy evaluable patients on study without documentation of disease progression 6 months from registration divided by the total number of evaluable patients enrolled on study. Kaplan-Meier methodology will be used to estimate the final success proportion (i.e. progression free at 6 months with a 95% confidence interval).","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Endometrial Cohort"},{"description":"Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Ovarian Cohort"},{"description":"Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG002","title":"Hepatocellular Cohort"},{"description":"Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG003","title":"Carcinoid Cohort"},{"description":"Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG004","title":"Islet Cell (Double Agent) Cohort"},{"description":"Patients receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG005","title":"Islet Cell (Bevacizumab-only) Cohort"}],"paramType":"NUMBER","populationDescription":"All patients that received study treatment and were evaluated for response are included in this analysis","reportingStatus":"POSTED","timeFrame":"6 months","title":"Progression Free Survival Rate","type":"PRIMARY","unitOfMeasure":"proportion of patients"}